Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet’s Syndrome

Anakinra for Difficult-to-Treat Neutrophilic Panniculitis: IL-1 Blockade as a Promising Treatment Option for Neutrophil-Mediated Inflammatory Skin Disease

(2010) Dan Lipsker et al.   DERMATOLOGY

Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome

(2010) Ioannis Mitroulis et al.   European Journal of Internal Medicine

Neutrophilic Dermatoses

(2009) Philip R. Cohen   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

A Mutation in the Nlrp3 Gene Causing Inflammasome Hyperactivation Potentiates Th17 Cell-Dominant Immune Responses

(2009) Guangxun Meng et al.   IMMUNITY

Etanercept Treatment in Sweet's Syndrome with Inflammatory Arthritis

(2009) N. L. AMBROSE et al.   JOURNAL OF RHEUMATOLOGY

Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome

(2008) A Delluc et al.   ANNALS OF THE RHEUMATIC DISEASES

Sweet Syndrome Presenting as Resistant Conjunctivitis

(2008) Guillaume Michel et al.   CORNEA

Primer: inflammasomes and interleukin 1β in inflammatory disorders

(2008) Leigh D Church et al.   Nature clinical practice. Rheumatology